This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

New Data On NovoTTF™ Therapy To Be Presented At The 2012 SNO Meeting

PORTSMOUTH, N.H., Nov. 14, 2012 /PRNewswire/ -- Novocure™, a commercial stage private oncology company, announced today that preclinical and clinical data from studies evaluating NovoTTF™ Therapy will be presented at the 17th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (SNO) in Washington, D.C.

The data presented sheds light on the subcellular mechanisms underlying the anti-cancer effect of NovoTTF Therapy and helps define which recurrent GBM patients respond best to this novel treatment modality.

"We made significant progress in 2012 conducting and supporting research that has the potential to improve the lives of cancer patients around the world," said Eilon Kirson, M.D., Ph.D., Novocure's Chief Science Officer and Head of Research and Development.  "We are pleased to present additional clinical data at SNO from the EF-11 pivotal trial, as well as to announce two presentations of pre-clinical data further examining the mechanism of action and efficacy of NovoTTF Therapy."

Detailed information about the NovoTTF Therapy presentations are listed below:

Date & Time: November 16, 2012, 7pm9pm Title: Analysis of the response profile to NovoTTF-100A treatment in patients with recurrent GBM: Time to effect, response duration and transient progressions in the EF-11 phase III trial Poster: NO-47 Presenter: Eric T. Wong, Beth Israel Deaconess Medical Center, Boston, MA

Date & Time: November 16, 2012, 7pm9pm Title: Efficacy of Tumor Treating Fields (TTFields) and/or radiotherapy (RT) in non-small cell lung cancer (NSCLC) cells Poster: ET-30 Presenter: Katarzyna Zielinska-Chomej, Karolinska Institutet, Stockholm, Sweden

Date & Time: November 17, 2012, 5:15pm7:15pm Title: Mitosis Interference of Cancer Cells by NovoTTF-100A Causes Decreased Cellular Viability Poster: CB-13 Presenter: Sze Xian Lee, Beth Israel Deaconess Medical Center, Boston, MA

In addition to the data presentations, Novocure will be sponsoring a symposium titled "A New Cancer Treatment Modality: Going Beyond Pharmacology with Tumor Treating Fields (TTFields)" presented by Eric T. Wong, M.D. (Beth Israel Deaconess Medical Center) and Manmeet Ahluwalia, M.D., (Cleveland Clinic) on November 17 th from 12pm to 1pm. The symposium will provide clinical perspectives for incorporating the NovoTTF™-100A System into the treatment paradigm for recurrent glioblastoma multiforme (GBM).

About GlioblastomaGlioblastoma is the most aggressive and most common form of primary brain tumor in the U.S. The disease affects approximately 10,000 Americans each year.  Historically, based on literature, the median overall survival time from initial diagnosis is 15 months with optimal treatment, and median survival from the time of tumor recurrence is only 3-5 months without additional effective treatment.  The disease is widely recognized as one of the deadliest forms of cancer.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,813.39 +1.20 0.01%
S&P 500 2,088.87 -0.27 -0.01%
NASDAQ 5,116.1430 +13.3350 0.26%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs